Page 209 - EJMO-9-1

Eurasian Journal of Medicine and
Oncology
Cost-effectiveness of nivolumab+chemo for gastric/GEJ cancer

with the ongoing development of personalized and Consent for publication
precision medicine, future pharmacoeconomic evaluations
should consider cost-effectiveness differences in drug Not applicable.
treatments for patient populations with varying genetic Availability of data
backgrounds or biomarkers, conducting more detailed
stratified analyses to support individualized treatment The datasets used and/or analyzed in this current study
decisions. From an economic perspective, future studies are available from published clinical studies and from the
could focus on developing more rational and sustainable corresponding author upon reasonable request.
drug usage policies that consider actual healthcare References
resources in different economic and cultural contexts.
Finally, as health economics methodologies continue 1. Bray F, Ferlay J, Soerjomataram I, Siegel RL, Torre LA,
to advance, future pharmacoeconomic research should Jemal A. Global cancer statistics 2018: GLOBOCAN
estimates of incidence and mortality worldwide for 36 cancers
emphasize interdisciplinary integration by combining in 185 countries. CA Cancer J Clin. 2018;68(6):394-424.
the latest developments in big data analysis, artificial
intelligence, and systems biology to develop more accurate doi: 10.3322/caac.21492
and efficient assessment tools. These methods will help 2. Ajani JA, D’Amico TA, Almhanna K, et al. Gastric cancer,
improve the precision of pharmacoeconomic research version 3.2016, NCCN clinical practice guidelines in
and enhance its practical guidance for clinical and policy- oncology. J Natl Compr Canc Netw. 2016;14(10):1286-1312.
making decisions. doi: 10.6004/jnccn.2016.0137

5. Conclusion 3. Gunderson LL. Gastric cancer--patterns of relapse after
surgical resection. Semin Radiat Oncol. 2002;12(2):150-161.
Overall, from the perspective of American payers, doi: 10.1053/srao.2002.30817
nivolumab plus chemotherapy may not be a cost-effective
choice for the first-line treatment of patients aged 18 years 4. Japanese Gastric Cancer Association. Japanese gastric
th
or older who are clinically or pathologically diagnosed cancer treatment guidelines 2018 (5 edition). Gastric
with locally advanced or metastatic G/GEJ/esophageal Cancer. 2021;24(1):1-21.
adenocarcinoma, particularly at a WTP threshold of doi: 10.1007/s10120-020-01042-y
$207,659 per QALY compared to chemotherapy alone. 5. Smyth EC, Verheij M, Allum W, et al. Gastric cancer: ESMO
Clinical Practice Guidelines for diagnosis, treatment and
Acknowledgments follow-up. Ann Oncol. 2016;27(Suppl 5):V38-V49.
None. doi: 10.1093/annonc/mdw350

Funding 6. Wang FH, Shen L, Li J, et al. The Chinese Society of Clinical
Oncology (CSCO): Clinical guidelines for the diagnosis and
The study was self-funded by the authors and did not rely treatment of gastric cancer. Cancer Commun Lond Engl.
on external funding sources. 2019;39(1):10.
doi: 10.1186/s40880-019-0349-9
Conflict of interest
7. Catenacci DVT, Tebbutt NC, Davidenko I, et al.
The authors declare that there is no conflict of interest. Rilotumumab plus epirubicin, cisplatin, and capecitabine
as first-line therapy in advanced MET-positive gastric
Author contributions or gastro-oesophageal junction cancer (RILOMET-1):
A randomised, double-blind, placebo-controlled, phase 3
Conceptualization: Ge-Li Li trial. Lancet Oncol. 2017;18(11):1467-1482.
Data curation: Jin Zhou, Xia Yin
Formal analysis: Jin Zhou, Han Zhan doi: 10.1016/S1470-2045(17)30566-1
Funding acquisition: Ge-Li Li 8. Fuchs CS, Shitara K, Di Bartolomeo M, et al. Ramucirumab
Writing – original draft: Jin Zhou, Jin Luo with cisplatin and fluoropyrimidine as first-line therapy in
Writing – review & editing: Wei Oy-Yang patients with metastatic gastric or junctional adenocarcinoma
(RAINFALL): A double-blind, randomised, placebo-
Ethics approval and consent to participate controlled, phase 3 trial. Lancet Oncol. 2019;20(3):420-435.

Not applicable as this study is based on a literature review doi: 10.1016/S1470-2045(18)30791-5
and modeling techniques. 9. Lordick F, Kang YK, Chung HC, et al. Capecitabine and

Volume 9 Issue 1 (2025) 201 doi: 10.36922/ejmo.7075